Public Misunderstandings Around Clinical Trials
"What does the general public not understand the most about clinical trials?" is the question we posed to three industry professionals at DIA 2023.
"What does the general public not understand the most about clinical trials?" is the question we posed to three industry professionals. And their answers span only a few of the challenges that remain in patient education and knowledge about the clinical research enterprise.
In this video, Kenneth Getz, Executive Director and Professor, Tufts Center for the Study of Drug Development and Founder, Board Chair, CISCRP; Janice Chang, CEO of TransCelerate BioPharma, and Greg Ball, Safety Data Scientist and founder, ASAP Process Consulting present their views on the topic.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025